Long-term safety follow-up with aficamten for adults with HCM
Treatments studied
Part of Heart & circulation clinical trials.
This study checks how safe and well-tolerated aficamten is over the long run in adults with hypertrophic cardiomyopathy (HCM). You may be eligible if you finished a prior Cytokinetics aficamten study and your heart pumping strength is in the required range.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You completed a previous Cytokinetics trial that tested aficamten
- Your heart pumping strength (LVEF) is at least 55% at the screening visit
- You have not taken mavacamten within the last 56 days
- You have not joined another research drug/device study within 1 month before screening
- Since your prior aficamten study, you have not needed new atrial fibrillation treatment within 30 days
- You have not had septal reduction treatment or a recent ICD placed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called aficamten in people with non-obstructive hypertrophic cardiomyopathy (a thickened heart muscle that affects how well the heart works). The goal is to see if it improves symptoms like fatigue and shortness of breath and helps you feel better in daily life.
This study tests switching from mavacamten to aficamten, two newer medicines that help improve heart function in people with a thickened heart muscle (HCM) that blocks blood flow. The goal is to see if aficamten works as well or better.
This study tests whether the drug mavacamten (Camzyos) improves blood flow in the heart's small vessels for people with obstructive hypertrophic cardiomyopathy. You will take mavacamten as prescribed and have a PET/CT scan to measure your heart's blood flow reserve.
This study collects real-world information about people with obstructive hypertrophic cardiomyopathy (HCM) who are being treated with mavacamten or other standard medicines. It aims to understand patient characteristics, treatment choices over time, and long-term outcomes.
This study tests whether mavacamten, a medication that may help the heart use energy better, can improve symptoms in people with obstructive hypertrophic cardiomyopathy. It aims to see if this drug helps with chest pain and shortness of breath, and improve overall heart function.
This study tests whether adding the drug mavacamten to a heart procedure (radiofrequency ablation) helps people with a thickened heart muscle that blocks blood flow. It may reduce symptoms like chest pain or shortness of breath.
Hear when a new Symptomatic Hypertrophic Cardiomyopathy (HCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.